690.00
690.00
Inclusive of all taxes
You Save: 0. Discount 0%
Product is not available
DAPAZIGA-10 Tablet is an advanced oral antidiabetic medication containing Dapagliflozin 10 mg, a selective SGLT2 inhibitor. It is primarily indicated for the management of Type 2 Diabetes Mellitus (T2DM), helping patients achieve better glycemic control by promoting urinary glucose excretion independent of insulin pathways. Manufactured by BluepillExpress under internationally certified GMP facilities, DAPAZIGA-10 offers high bioavailability, excellent patient tolerance, and strong safety standards—making it ideal for global third-party manufacturing and pharmaceutical distribution partnerships.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
DAPAZIGA-10 Tablet is a state-of-the-art medication developed for the management of Type 2 Diabetes Mellitus (T2DM). It features Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which has significantly transformed the landscape of antidiabetic therapy due to its insulin-independent mechanism, cardio-renal protection, and weight-reducing effects.
Dapagliflozin works by selectively inhibiting the SGLT2 protein in the renal proximal tubules, thereby reducing glucose reabsorption in the kidneys and increasing urinary glucose excretion. This not only lowers fasting and postprandial blood glucose levels but also contributes to modest weight loss and reduced systolic blood pressure, making it an excellent choice in the holistic management of diabetic patients.
DAPAZIGA-10 is manufactured under WHO-GMP compliant facilities and is tailored for third-party manufacturing, export, and private labeling under BluepillExpress, India's globally trusted pharmaceutical exporter.
Pharmacological Class
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor
Antihyperglycemic Agent
Mechanism of Action
Dapagliflozin selectively inhibits SGLT2 in the kidneys, reducing glucose reabsorption and promoting its elimination via urine. This mechanism is independent of insulin secretion or action, making it beneficial even in insulin-resistant patients.
Indications
Type 2 Diabetes Mellitus (as monotherapy or combination therapy)
To reduce the risk of hospitalization for heart failure in patients with T2DM and established cardiovascular disease
Adjunct to diet and exercise for glycemic control
Key Benefits
Improves Glycemic Control: Effectively lowers HbA1c, fasting blood sugar, and postprandial glucose.
Weight Reduction: Promotes calorie loss through glucosuria, leading to modest weight loss.
Blood Pressure Control: Helps reduce systolic BP without increasing heart rate.
Cardio-Renal Benefits: Clinical trials show reduction in cardiovascular events and protection of kidney function.
Low Risk of Hypoglycemia: As it doesn’t stimulate insulin release, the hypoglycemia risk is minimal when used alone.
Convenient Once-Daily Dose: Promotes better patient adherence and compliance.
